Last reviewed · How we verify
High-dose CAR-T cells group
High-dose CAR-T cells group is a CAR-T cell therapy Biologic drug developed by Guangzhou Women and Children's Medical Center. It is currently in Phase 3 development for Hematologic malignancies (specific indication not detailed in available information).
High-dose CAR-T cells are engineered immune cells that express chimeric antigen receptors to recognize and kill cancer cells expressing specific tumor antigens.
High-dose CAR-T cells are engineered immune cells that express chimeric antigen receptors to recognize and kill cancer cells expressing specific tumor antigens. Used for Hematologic malignancies (specific indication not detailed in available information).
At a glance
| Generic name | High-dose CAR-T cells group |
|---|---|
| Sponsor | Guangzhou Women and Children's Medical Center |
| Drug class | CAR-T cell therapy |
| Target | Tumor-associated antigens (specific target antigen not specified) |
| Modality | Biologic |
| Therapeutic area | Oncology |
| Phase | Phase 3 |
Mechanism of action
CAR-T cell therapy involves extracting a patient's T cells, genetically modifying them to express a chimeric antigen receptor (CAR) that targets tumor-associated antigens, and reinfusing the expanded cells at high doses to mount a potent anti-tumor immune response. The high-dose approach aims to maximize therapeutic efficacy by increasing the number of tumor-targeting cells available to attack malignant cells.
Approved indications
- Hematologic malignancies (specific indication not detailed in available information)
Common side effects
- Cytokine release syndrome
- Neurotoxicity
- Cytopenias
- Infections
Key clinical trials
- U69-CART-Cells For R/R T-ALL (PHASE1)
- GB5005 CART-cell Injection in the Treatment of Patients With CD19-positive RR B-NHL (PHASE1)
- A Pilot Study of Emapalumab for the Treatment of CAR T-Cell Therapy-Associated Prolonged Cytopenia (PHASE2)
- Study of Therapeutic Efficacy of Anti-CD19 CAR-T Cells in Refractory Systemic Lupus Erythematosus (PHASE1)
- A Phase 1 Study of JV-213 Autologous CD79b-targeting Chimeric Antigen Receptor T-cell Therapy in Adults With Relapsed or Refractory B-cell Lymphomas (PHASE1)
- A Study to Find a Suitable Dose of ASP2802 in People With CD20-positive B-cell Lymphomas (PHASE1)
- MRD-Adaptive Guided Immunotherapy With CAR-T for Transplant-Ineligible Patients With Multiple Myeloma (PHASE2)
- C7R-GD2.CART Cells for Patients With Relapsed or Refractory Neuroblastoma and Other GD2 Positive Cancers (GAIL-N) (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- High-dose CAR-T cells group CI brief — competitive landscape report
- High-dose CAR-T cells group updates RSS · CI watch RSS
- Guangzhou Women and Children's Medical Center portfolio CI
Frequently asked questions about High-dose CAR-T cells group
What is High-dose CAR-T cells group?
How does High-dose CAR-T cells group work?
What is High-dose CAR-T cells group used for?
Who makes High-dose CAR-T cells group?
What drug class is High-dose CAR-T cells group in?
What development phase is High-dose CAR-T cells group in?
What are the side effects of High-dose CAR-T cells group?
What does High-dose CAR-T cells group target?
Related
- Drug class: All CAR-T cell therapy drugs
- Target: All drugs targeting Tumor-associated antigens (specific target antigen not specified)
- Manufacturer: Guangzhou Women and Children's Medical Center — full pipeline
- Therapeutic area: All drugs in Oncology
- Indication: Drugs for Hematologic malignancies (specific indication not detailed in available information)
- Compare: High-dose CAR-T cells group vs similar drugs
- Pricing: High-dose CAR-T cells group cost, discount & access